State Street Corp Purchases New Holdings in Astrana Health, Inc. (NASDAQ:ASTH)

State Street Corp purchased a new stake in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,587,270 shares of the company's stock, valued at approximately $91,966,000. State Street Corp owned about 2.82% of Astrana Health as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in ASTH. GAMMA Investing LLC acquired a new position in Astrana Health in the third quarter valued at approximately $34,000. Nisa Investment Advisors LLC acquired a new stake in shares of Astrana Health in the 3rd quarter worth approximately $35,000. KBC Group NV acquired a new stake in shares of Astrana Health in the third quarter valued at approximately $70,000. Quarry LP purchased a new position in Astrana Health in the 3rd quarter valued at about $77,000. Finally, Quest Partners LLC acquired a new stake in shares of Astrana Health during the third quarter worth $133,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ASTH. KeyCorp initiated coverage on Astrana Health in a report on Friday, October 11th. They issued a "sector weight" rating on the stock. TD Cowen began coverage on shares of Astrana Health in a research report on Monday, October 14th. They set a "buy" rating and a $66.00 target price on the stock. BTIG Research raised their price objective on Astrana Health from $60.00 to $70.00 and gave the company a "buy" rating in a research note on Thursday, October 3rd. Finally, Robert W. Baird upped their target price on shares of Astrana Health from $67.00 to $86.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $65.17.

Astrana Health Stock Performance

Shares of ASTH stock traded down $1.27 during trading on Tuesday, reaching $35.52. The company had a trading volume of 295,676 shares, compared to its average volume of 213,264. The company has a market capitalization of $2.00 billion, a PE ratio of 27.38, a PEG ratio of 1.80 and a beta of 1.13. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The firm's 50 day simple moving average is $49.04 and its two-hundred day simple moving average is $48.12. Astrana Health, Inc. has a one year low of $34.11 and a one year high of $63.20.

Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $478.71 million during the quarter, compared to the consensus estimate of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period in the prior year, the firm earned $0.47 EPS. Sell-side analysts forecast that Astrana Health, Inc. will post 1.16 earnings per share for the current year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.